Recombinant Human Serine protease HTRA2, mitochondrial (HTRA2)

What is HTRA2 and what are its primary biological functions?

HTRA2 (High Temperature Requirement Protein A2) is a mitochondrial serine protease with versatile biological functions. It serves as an important regulator of apoptosis and is essential for neuronal cell survival and mitochondrial homeostasis. The protein is primarily localized in the intermembrane space of mitochondria where it functions as a chaperone molecule by monitoring and controlling protein folding . HTRA2 is involved in apoptotic regulation through its ability to degrade inhibitor-of-apoptosis proteins (IAPs) . The immature form of HTRA2 is anchored to the inner mitochondrial membrane by a transmembrane motif and is released as an active 36-kDa protein fragment through autocatalytic processing .

What is the domain architecture of HTRA2?

HTRA2 comprises several functional domains and binding motifs that contribute to its activity and regulation:

• Mitochondrial N-terminal localization signal (MLS)

• Transmembrane segment (TM)

• Inhibitor of apoptosis (IAP)-binding motif (IBM)

• Serine protease domain containing the catalytic triad

• PDZ domain for protein-protein interactions

The interaction between these domains, particularly between the PDZ and protease domains, is critical for regulating HTRA2's proteolytic activity. Disruption of the PDZ/protease interaction through engagement with specific peptide ligands can significantly enhance HTRA2's proteolytic activity .

How is HTRA2 implicated in neurodegenerative diseases?

HTRA2 appears to be a key player in neurodegenerative diseases. Loss of HTRA2 protease function causes neurodegeneration, while overactivation of its proteolytic function is associated with cell death and inflammation . Interestingly, HTRA2 protein activity is increased in brain tissues of Alzheimer's disease patients and is thought to promote neuroprotection by enhancing autophagic processes . Additionally, increased HTRA2 activity promotes the degradation of mutant proteins (e.g., A53T α-synuclein) through autophagy and may be an important mechanism for amyloid plaque removal in Alzheimer's disease .

How do divalent ions modulate HTRA2 activity and what are the implications for experimental design?

Different divalent ions have distinct effects on HTRA2's proteolytic activity, which is crucial to consider when designing experiments. Calcium (Ca²⁺) significantly enhances HTRA2 activity by doubling the Vmax value and decreasing the KM value by about 50% compared to standard buffer conditions. This results in approximately a fourfold increase in kcat/kM value .

Magnesium (Mg²⁺) has a different effect: it lowers the KM value to about 25% of that in standard buffer but markedly decreases Vmax, resulting in an almost twofold increase in kcat/kM . In contrast, zinc (Zn²⁺) and copper (Cu²⁺) completely inhibit protease activity .

The molecular basis for calcium's effect involves shifting HTRA2 toward a "pre-open" state, facilitating easier access for activating peptides to binding sites buried at the PDZ:protease domain interface, resulting in reduced dissociation constants .

What roles do structural dynamics play in HTRA2 activation and how can researchers investigate them?

HTRA2 undergoes complex structural dynamics that are crucial for its activation. Key regions involved in these dynamics include:

• The amino-terminal helix α1, which plays a previously unknown role in the HTRA2 activation cascade

• The PDZ domain, which experiences metal ion-modulated dynamics

• Regions of high structural frustration, particularly helices α1 and α5 and the LA loop, which experience micro-to-millisecond conformational exchange in the apo state

Researchers can investigate these dynamics using multiple complementary techniques:

• Paramagnetic relaxation enhancement (PRE) experiments to track domain movements

• Multi-quantum (MQ) CPMG relaxation rate measurements to assess differences in dynamics between apo and peptide-bound states

• Analysis of local structural frustration to identify hotspots of highly frustrated regions that correlate with conformational exchange

These approaches have revealed that calcium binding destabilizes the domain interface, leading to partial opening, while the addition of activating peptides causes more substantial conformational changes throughout the protein .

How do allosteric mechanisms regulate HTRA2 activity and how might this inform therapeutic strategies?

HTRA2 activity is regulated through complex allosteric mechanisms including:

• Transient oligomerization and interprotomer cooperativity

• Metal ion binding (particularly Ca²⁺) that modulates PDZ domain dynamics

• Peptide binding at the PDZ:protease domain interface

• Conformational changes in regulatory loops, particularly involving helices α1 and α5

Understanding these mechanisms provides potential therapeutic targets:

• Synthetic peptides like ASGYTFTNYGLSWVR can bind HTRA2 with high affinity and trigger neuroprotection in glaucoma models

• Modulating HTRA2 activity through specific peptide ligands or small molecules that target allosteric sites could provide therapeutic benefits in neurodegenerative diseases

• Targeting structural elements involved in activation (e.g., helix α1 or α5) might offer new approaches to control HTRA2 activity in disease contexts

What are effective strategies for studying HTRA2-protein interactions in retinal tissue?

Co-immunoprecipitation (Co-IP) coupled with mass spectrometry provides an effective approach for studying HTRA2 interactions in retinal tissue. A methodological protocol based on published research includes:

• Prepare homogenized retinal tissue (e.g., from house swine, Sus scrofa)

• Add recombinant HTRA2 with a C-terminal 6xHis-tag motif to the homogenate

• Use HisPur Ni-NTA magnetic beads to capture the recombinant HTRA2 and its interaction partners

• Include appropriate controls and experimental groups:

  • Control homogenate (CTRL group)

  • Homogenate with recombinant HTRA2 (HTRA2 group)

  • Homogenate with recombinant HTRA2 and UCF-101 inhibitor (UCF-101 group)

  • Homogenate with recombinant HTRA2 and synthetic CDR peptide (CDR group)

This approach allows for the identification of direct protein interaction partners of HTRA2 in retinal tissue and the evaluation of how these interactions are influenced by inhibitors or activators .

How can researchers effectively measure HTRA2 proteolytic activity in experimental settings?

Researchers can employ fluorescence-based assays to quantitatively measure HTRA2 proteolytic activity. Key methodological considerations include:

• Use of fluorescent substrates that enable continuous monitoring of proteolytic activity

• Testing with varying substrate concentrations to determine kinetic parameters (kcat/KM)

• Inclusion of activating peptides (e.g., DD-PDZOpt) at defined concentrations

• Careful buffer selection, including consideration of metal ion content

In standard assay buffer without additional metal ions, researchers can expect a kcat/KM of approximately 85 M⁻¹s⁻¹ when using sub-saturating concentrations of activating peptide (e.g., 50 μM DD-PDZOpt) .

For comprehensive analysis, researchers should consider performing parallel assays with:

• Fixed substrate concentration and varying activator peptide concentration

• Fixed activator peptide concentration and varying substrate concentration

• Various metal ion supplementations (Ca²⁺, Mg²⁺, Zn²⁺, Cu²⁺) to understand their modulatory effects

What techniques are most informative for studying the structural dynamics of HTRA2?

Multiple complementary techniques provide insights into HTRA2 structural dynamics:

• Nuclear magnetic resonance (NMR) spectroscopy:

  • Multi-quantum (MQ) CPMG relaxation rate measurements at different frequencies (e.g., 25 and 750 Hz)

  • Assessment of S²axis·τC values to characterize pico- to nanosecond timescale dynamics

  • Methyl NOE pattern analysis in full-length HTRA2

• Paramagnetic relaxation enhancement (PRE) experiments:

  • Construction of single cysteine mutants (e.g., HTRA2 S306A, S145C)

  • Side-specific attachment of paramagnetic spin labels (MTSL)

  • Comparison of PRE effects under different conditions (apo state, metal-bound, peptide-bound)

• Structural frustration analysis:

  • Computational analysis to identify regions of high structural frustration

  • Correlation of frustrated regions with experimental observations of conformational exchange

These techniques have revealed that regions experiencing significant micro-to-millisecond dynamics in the apo state include helices α1 and α5 and the LA loop, which correlate well with regions of high structural frustration .

How does HTRA2 dysfunction contribute to neurodegenerative diseases and what are the therapeutic implications?

HTRA2 dysfunction contributes to neurodegenerative diseases through multiple mechanisms:

• Loss of HTRA2 protease function causes neurodegeneration, likely due to impaired protein quality control in mitochondria

• Overactivation of HTRA2's proteolytic function is associated with cell death and inflammation

• In Alzheimer's disease, HTRA2 protein activity is increased in brain tissues, potentially as a compensatory mechanism to promote neuroprotection through enhanced autophagy

• HTRA2 promotes degradation of mutant proteins like A53T α-synuclein (associated with Parkinson's disease) through autophagy

These findings suggest HTRA2 may be a key therapeutic target in neurodegenerative diseases. Recent research demonstrated that a synthetic peptide (ASGYTFTNYGLSWVR) encoding the hypervariable sequence part of an antibody showed high affinity for HTRA2 and triggered neuroprotection in an in vitro organ culture model for glaucoma . This suggests that modulating HTRA2 activity—rather than simply inhibiting it—may offer therapeutic benefits.

What research approaches can help resolve the paradoxical roles of HTRA2 in neuroprotection versus neurodegeneration?

HTRA2 exhibits seemingly contradictory roles—both protecting against and potentially contributing to neurodegeneration. Research approaches to resolve this paradox include:

• Tissue-specific and disease-stage-specific profiling of HTRA2 activity and expression

• Identification and characterization of endogenous regulators of HTRA2 activity

• Investigation of HTRA2's substrate specificity under different pathological conditions

• Development of conditional knockout models to study HTRA2 function in specific cell types and at different disease stages

• Comparative analysis of HTRA2 activity modulation across different neurodegenerative disease models

A particularly promising approach involves using modulatory peptides or small molecules that can fine-tune HTRA2 activity rather than completely inhibiting or activating it. The synthetic CDR1 peptide mentioned in the research represents such a modulator, showing neuroprotective effects in glaucoma models .